Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 6, 2015, Pages 649-663

  Lundell, L ^a   Vieth, M ^b   Gibson, F ^c   Nagy, P ^d   Kahrilas, P J ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTE OF PATHOLOGY   (Germany)

^c OXFORD PHARMAGENESIS LTD   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; CELL HYPERPLASIA; ENTEROCHROMAFFIN LIKE CELL; GASTRIN BLOOD LEVEL; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HYPERGASTRINEMIA; LONG TERM CARE; NEUROENDOCRINE TUMOR; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; STOMACH; STOMACH ADENOCARCINOMA; STOMACH ATROPHY; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; DRUG ADMINISTRATION; HELICOBACTER INFECTIONS; HYPERPLASIA; ISOLATION AND PURIFICATION; PATHOLOGY; STOMACH TUMOR;

DRUG ADMINISTRATION SCHEDULE; ENTEROCHROMAFFIN-LIKE CELLS; GASTRINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYPERPLASIA; NEUROENDOCRINE TUMORS; PROTON PUMP INHIBITORS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84939562887     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13324     Document Type: Article

References (96)

1. Stedman CA, Barclay ML,. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
2. Savarino V, Di Mario F, Scarpignato C,. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res 2009; 59: 135-53.
3. McCarthy DM,. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26: 624-31.
4. DeVault KR, Castell DO,. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
5. Lanza FL, Chan FK, Quigley EM,. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
6. Malfertheiner P, Megraud F, O'Morain CA, et al,. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
7. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al,. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
8. Talley NJ,. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129: 1753-5.
9. Katz PO, Gerson LB, Vela MF,. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-28.
10. El-Serag HB, Sweet S, Winchester CC, Dent J,. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-80.
11. Heidelbaugh JJ, Kim AH, Chang R, Walker PC,. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012; 5: 219-32.
12. Forgacs I, Loganayagam A,. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2-3.
13. Freston JW, Jackson RL, Huang B, Ballard ED 2nd,. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002; 62: 1173-84.
14. Nocon M, Labenz J, Jaspersen D, et al,. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care-results from the ProGERD study. Aliment Pharmacol Ther 2007; 25: 715-22.
15. Pounder R, Smith J,. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990; 19: 141-53.
16. Koop H, Klein M, Arnold R,. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 1990; 4: 131-8.
17. Walsh JH,. Role of gastrin as a trophic hormone. Digestion 1990; 47 (Suppl. 1): 11-6; discussion 49-52.
18. Wolfe MM, Soll AH,. The physiology of gastric acid secretion. N Engl J Med 1988; 319: 1707-15.
19. Wang TC, Koh TJ, Varro A, et al,. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest 1996; 98: 1918-29.
20. Modlin IM, Zhu Z, Tang LH, et al,. Evidence for a regulatory role for histamine in gastric enterochromaffin-like cell proliferation induced by hypergastrinemia. Digestion 1996; 57: 310-21.
21. Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E,. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 1988; 16: 267-72.
22. Havu N,. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 (Suppl. 1): 42-55.
23. Havu N, Mattsson H, Ekman L, Carlsson E,. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 1990; 45: 189-95.
24. Larsson H, Carlsson E, Mattsson H, et al,. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391-9.
25. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G,. Pharmacology and toxicology of omeprazole-with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 1986; 118: 31-8.
26. Lee H, Hakanson R, Karlsson A, Mattsson H, Sundler F,. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. Digestion 1992; 51: 125-32.
27. Poynter D, Pick CR, Harcourt RA, et al,. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 1985; 26: 1284-95.
28. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E,. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 1991; 100: 311-9.
29. Graham DY, Genta RM,. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008; 10: 543-7.
30. Robinson M,. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999; 13 (Suppl. 5): 5-10.
31. Sheen E, Triadafilopoulos G,. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56: 931-50.
32. Tepes B,. Long-term acid inhibition: benefits and harms. Dig Dis 2011; 29: 476-81.
33. Dawson R, Manson JM,. Omeprazole in oesophageal reflux disease. Lancet 2000; 356: 1770-1.
34. Haga Y, Nakatsura T, Shibata Y, et al,. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci 1998; 43: 253-7.
35. Jianu CS, Fossmark R, Viset T, et al,. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644-9.
36. Jianu CS, Lange OJ, Viset T, et al,. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012; 47: 64-7.
37. Graham DY, Klein PD, Opekun AR, Boutton TW,. Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis 1988; 157: 777-80.
38. Kosunen TU, Hook J, Rautelin HI, Myllyla G,. Age-dependent increase of Campylobacter pylori antibodies in blood donors. Scand J Gastroenterol 1989; 24: 110-4.
39. Sanduleanu S, Stridsberg M, Jonkers D, et al,. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13: 145-53.
40. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al,. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 605-12.
41. Jassel SV, Ardill JE, Fillmore D, Bamford KB, O'Connor FA, Buchanan KD,. The rise in circulating gastrin with age is due to increases in gastric autoimmunity and Helicobacter pylori infection. QJM 1999; 92: 373-7.
42. Correa P, Piazuelo MB,. The gastric precancerous cascade. J Dig Dis 2012; 13: 2-9.
43. Kuipers EJ, Uyterlinde AM, Pena AS, et al,. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 1401-6.
44. Larkin CJ, Watson RGP, Sloan JM, Stevenson M, Ardill JE, Buchanan D,. Distribution of atrophy in Helicobacter pylori-infected subjects taking proton pump inhibitors. Scand J Gastroenterol 2000; 35: 578-82.
45. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH,. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-6.
46. Moayyedi P, Wason C, Peacock R, et al,. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 206-14.
47. Uemura N, Okamoto S, Yamamoto S, et al,. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
48. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al,. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
49. Editor's update. Am J Gastroenterol 1997; 92 (Suppl.): 55-6.
50. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P,. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 41: 740-7.
51. Klinkenberg-Knol EC, Nelis F, Dent J, et al,. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
52. Lundell L, Havu N, Miettinen P, et al,. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23: 639-47.
53. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ,. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999; 13: 49-57.
54. Fiocca R, Mastracci L, Attwood SE, et al,. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012; 36: 959-71.
55. Fujimoto K, Hongo M,. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern Med 2011; 50: 179-88.
56. Geboes K, Dekker W, Mulder CJ, Nusteling K,. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001; 15: 1819-26.
57. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS,. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol 2003; 98: 1257-65.
58. Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H,. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther 2011; 33: 829-36.
59. Lundell L, Miettinen P, Myrvold HE, et al,. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999; 117: 319-26.
60. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E,. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 247-53.
61. Uemura N, Okamoto S, Yamamoto S, et al,. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 2000; 14: 1345-52.
62. Callreus T,. Sentinel systems are needed for long term adverse drug reactions. BMJ 2005; 330: 255-6.
63. Schuemie MJ, Trifiro G, Coloma PM, Ryan PB, Madigan D,. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: the exposure-adjusted self-controlled case series. Stat Methods Med Res 2014; DOI 10.1177/0962280214527531. [Epub ahead of print].
64. Metz DC,. Long-term use of proton-pump inhibitor therapy. Gastroenterol Hepatol (N Y) 2008; 4: 322-5.
65. Guyatt GH, Oxman AD, Vist GE, et al,. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
66. Bardhan KD, Bishop AE, Polak JM, et al,. Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis 2005; 37: 10-22.
67. Brunner GH, Lamberts R, Creutzfeldt W,. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 1990; 47 (Suppl. 1): 64-8.
68. Brunner G, Arnold R, Hennig U, Fuchs W,. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1993; 7 (Suppl. 1): 51-5.
69. Hage E, Hendel L, Gustafsen J, Hendel J,. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole. Eur J Gastroenterol Hepatol 2003; 15: 781-9.
70. Hendel L, Hage E, Hendel J, Stentoft P,. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6: 565-77.
71. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B,. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol 2005; 17: 559-66.
72. Brunner G, Athmann C, Schneider A,. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47.
73. Eissele R, Brunner G, Simon B, Solcia E, Arnold R,. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17.
74. Freston JW, Hisada M, Peura DA, et al,. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2009; 29: 1249-60.
75. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al,. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
76. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E,. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
77. Lamberts R, Brunner G, Solcia E,. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205-13.
78. Price AB,. The Sydney System: histological division. J Gastroenterol Hepatol 1991; 6: 209-22.
79. Dixon MF, Genta RM, Yardley JH, Correa P,. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
80. Solcia E, Bordi C, Creutzfeldt W, et al,. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185-200.
81. Creutzfeldt W,. The achlorhydria-carcinoid sequence: role of gastrin. Digestion 1988; 39: 61-79.
82. Solcia E, Rindi G, Havu N, Elm G,. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol Suppl 1989; 166: 129-37; discussion 138-129.
83. Bardram L, Thomsen P, Stadil F,. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome. Digestion 1986; 35 (Suppl. 1): 116-22.
84. Borch K, Renvall H, Liedberg G,. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88: 638-48.
85. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E,. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994-1006.
86. Freston JW,. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51 (Suppl. 1): 102-14.
87. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R,. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51 (Suppl. 1): 82-92.
88. Song H, Zhu J, Lu D,. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014; 12: CD010623.
89. Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A,. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001; 57: 89-91.
90. Johnston SC, Hauser SL,. The value of a case report. Ann Neurol 2007; 62: A11-2.
91. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al,. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12-20.
92. van Grieken NC, Meijer GA, Weiss MM, et al,. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. Am J Gastroenterol 2001; 96: 2882-6.
93. Bateman DN, Colin-Jones D, Hartz S, et al,. Mortality study of 18 000 patients treated with omeprazole. Gut 2003; 52: 942-6.
94. Kuipers EJ,. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55: 1217-21.
95. Poulsen AH, Christensen S, McLaughlin JK, et al,. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 2009; 100: 1503-7.
96. Guggenheim DE, Shah MA,. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013; 107: 230-6.